News
Market and company headlines
COLLAll
Loading
08:00Oct 211 Story
10:00-13:00Oct 192 Stories
Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement
As previously disclosed, Collegium Pharmaceutical, Inc. (the "Company") is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH ("Grünenthal") (as amended, the
COLL vs. DSNKY: Which Stock Is the Better Value Option?
COLL vs. DSNKY: Which Stock Is the Better Value Option?
08:00Oct 171 Story
08:00Oct 161 Story
13:00Oct 91 Story
02:00Oct 71 Story
08:00Oct 61 Story
02:00Oct 51 Story
05:00Sep 301 Story
05:00Sep 281 Story
02:00Sep 231 Story
06:00Sep 221 Story
16:00Sep 151 Story
07:00-09:00Sep 92 Stories
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49
Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $58 to $49.
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45
Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.
02:00Sep 31 Story
05:00Aug 191 Story
02:00-10:00Aug 72 Stories
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43
Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.
Collegium Pharmaceutical, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Collegium Pharmaceutical, Inc.
10:00Aug 62 Stories
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsIan Karp - Head of Investor RelationsVikram...
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.
03:00-09:00Aug 62 Stories
Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance
Collegium Pharma Q2 beats EPS but misses revenue; cuts FY product revenue guidance, stock falls ~11%. ADHD growth offsets pain portfolio weakness.
Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est
Collegium Pharmaceutical (NASDAQ:COLL) lowers FY2026 sales outlook from $865.000 million-$895.000 million to $825.000 million-$855.000 million vs $872.278 million estimate.